Expanded Access to ABBV-706
NCT07310277 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-01-29
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-706 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
- DRUG
-
ABBV-706
Intravenous (IV) Infusion
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
NCT04227028 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
NCT02475382 ·Status: NO_LONGER_AVAILABLE
-
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
NCT00130780 ·Status: COMPLETED ·Phase: PHASE2
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
NCT07250477 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
NCT02250326 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
NCT06834074 ·Status: AVAILABLE
-
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
NCT00369070 ·Status: TERMINATED ·Phase: PHASE2
-
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
NCT04807114 ·Status: RECRUITING
-
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
NCT00436332 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
NCT00717938 ·Status: COMPLETED ·Phase: PHASE3
-
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
NCT01562028 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects
NCT04939662 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840 ·Status: RECRUITING ·Phase: PHASE1
-
Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
NCT01279798 ·Status: NO_LONGER_AVAILABLE
-
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
NCT00022243 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
NCT00050830 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
NCT00094094 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT01966003 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
NCT00073723 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT05513703 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
NCT07099898 ·Status: RECRUITING ·Phase: PHASE3
-
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
NCT06064500 ·Status: APPROVED_FOR_MARKETING
-
S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer
NCT00074295 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
NCT00130728 ·Status: COMPLETED ·Phase: PHASE3